RU2438706C2 - Антитела к амилоиду бета 4, имеющие гликозилированную вариабельную область - Google Patents

Антитела к амилоиду бета 4, имеющие гликозилированную вариабельную область Download PDF

Info

Publication number
RU2438706C2
RU2438706C2 RU2008128138/10A RU2008128138A RU2438706C2 RU 2438706 C2 RU2438706 C2 RU 2438706C2 RU 2008128138/10 A RU2008128138/10 A RU 2008128138/10A RU 2008128138 A RU2008128138 A RU 2008128138A RU 2438706 C2 RU2438706 C2 RU 2438706C2
Authority
RU
Russia
Prior art keywords
seq
antibody molecule
composition according
heavy chain
glycosylated
Prior art date
Application number
RU2008128138/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2008128138A (ru
Inventor
Хансрюди ЛЁЧЕР (CH)
Хансрюди ЛЁЧЕР
Вальтер ХУБЕР (CH)
Вальтер ХУБЕР
Диана ШУБАУЕР (CH)
Диана ШУБАУЕР
Карл ВЕЙЕР (DE)
Карл Вейер
Манфред БРОКХАУЗ (CH)
Манфред Брокхауз
Бернд БОРМАНН (CH)
Бернд Борманн
Ханс КОЛЛЬ (DE)
Ханс КОЛЛЬ
Андреас ШАУБМАР (DE)
Андреас Шаубмар
Курт ЛАНГ (DE)
Курт Ланг
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2008128138A publication Critical patent/RU2008128138A/ru
Application granted granted Critical
Publication of RU2438706C2 publication Critical patent/RU2438706C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2008128138/10A 2005-12-12 2006-12-11 Антитела к амилоиду бета 4, имеющие гликозилированную вариабельную область RU2438706C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05027090.9 2005-12-12
EP05027090 2005-12-12

Publications (2)

Publication Number Publication Date
RU2008128138A RU2008128138A (ru) 2010-01-20
RU2438706C2 true RU2438706C2 (ru) 2012-01-10

Family

ID=37745986

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008128138/10A RU2438706C2 (ru) 2005-12-12 2006-12-11 Антитела к амилоиду бета 4, имеющие гликозилированную вариабельную область

Country Status (33)

Country Link
US (2) US8906370B2 (https=)
EP (2) EP1960428B1 (https=)
JP (1) JP5145241B2 (https=)
KR (2) KR101401159B1 (https=)
CN (2) CN102659943B (https=)
AR (1) AR057233A1 (https=)
AT (1) ATE517923T1 (https=)
AU (1) AU2006326301B2 (https=)
BR (1) BRPI0619605B8 (https=)
CA (1) CA2632828C (https=)
CR (1) CR10000A (https=)
CY (1) CY1114783T1 (https=)
DK (1) DK1960428T3 (https=)
DO (1) DOP2006000278A (https=)
EC (1) ECSP088524A (https=)
ES (1) ES2368591T3 (https=)
IL (1) IL191004A (https=)
JO (1) JO2824B1 (https=)
MA (1) MA30038B1 (https=)
MY (1) MY155286A (https=)
NO (1) NO346105B1 (https=)
NZ (1) NZ568241A (https=)
PE (3) PE20100684A1 (https=)
PL (1) PL1960428T3 (https=)
PT (1) PT1960428E (https=)
RS (1) RS52004B (https=)
RU (1) RU2438706C2 (https=)
SI (1) SI1960428T1 (https=)
TW (1) TWI382990B (https=)
UA (1) UA99097C2 (https=)
UY (1) UY30003A1 (https=)
WO (1) WO2007068429A1 (https=)
ZA (1) ZA200805038B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
MY155286A (en) * 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
JP5512514B2 (ja) * 2007-06-29 2014-06-04 エフ．ホフマン−ラ ロシュ アーゲー 改善された免疫グロブリンの産生をもたらす重鎖変異体
ES2840725T3 (es) * 2007-08-20 2021-07-07 Glaxo Group Ltd Procedimiento de producción
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
BRPI0820819B1 (pt) * 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CN107233569B (zh) * 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
RS54644B1 (sr) * 2012-03-08 2016-08-31 F. Hoffmann-La Roche Ag Formulacija abeta antitela
HUE045144T2 (hu) * 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
EP2934589B1 (en) * 2012-12-18 2021-01-13 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
CN105899192B (zh) 2013-11-22 2019-08-13 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
SI3337812T1 (sl) * 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
HUE057085T2 (hu) * 2015-10-16 2022-04-28 Hoffmann La Roche Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer
KR102776187B1 (ko) 2015-11-09 2025-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
EP3427183A1 (en) * 2016-03-10 2019-01-16 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US20200113854A1 (en) * 2017-05-30 2020-04-16 Morinaga Milk Industry Co., Ltd. Composition for Improving Brain Function
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
IL302740A (en) * 2020-11-16 2023-07-01 Hoffmann La Roche Fab high mannose glycoforms
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114720543B (zh) * 2022-04-06 2026-02-24 苏州大学 一种基于固相糖蛋白t抗原糖肽富集和酶切分析的方法
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
CN121620524A (zh) 2023-08-09 2026-03-06 豪夫迈·罗氏有限公司 抗A-β蛋白抗体、方法及其用途
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN117783359B (zh) * 2023-12-28 2024-12-31 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167661C2 (ru) * 1994-08-08 2001-05-27 Фармация и Апджон С.п.А. Производные антрациклинона и их использование при амилоидозе
WO2003070760A2 (en) * 2002-02-20 2003-08-28 F. Hoffmann-La Roche Ag Anti-amyloid beta antibodies and their use
RU2260599C2 (ru) * 1999-03-04 2005-09-20 Прикис Фамэсьютикэлс Инкопэрейтид МОДУЛЯТОР АГРЕГАЦИИ ПЕПТИДА β-АМИЛОИДА ДЛЯ ИНГИБИРОВАНИЯ АГРЕГАЦИИ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА ИЛИ ДЛЯ ЛЕЧЕНИЯ СУБЪЕКТА ОТ НАРУШЕНИЯ, АССОЦИИРОВАННОГО С β -АМИЛОИДОЗОМ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЕТЕКЦИИ В БИОЛОГИЧЕСКОМ ОБРАЗЦЕ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
WO1996039628A1 (en) * 1995-06-06 1996-12-12 Stemcell Therapeutics L.L.C. GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
EP1209969A2 (en) 1999-08-31 2002-06-05 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
MXPA02005576A (es) 1999-11-29 2002-12-13 Neurochem Inc Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ATE385811T1 (de) 2000-12-19 2008-03-15 Palatin Technologies Inc Identifizierung zielgerichteter faltungsstellen in peptiden und proteinen
EP2165714B1 (en) 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
EP1385544B1 (en) 2001-04-30 2008-09-24 Eli Lilly And Company Humanized antibodies
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
PT1944040E (pt) * 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MY155286A (en) * 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167661C2 (ru) * 1994-08-08 2001-05-27 Фармация и Апджон С.п.А. Производные антрациклинона и их использование при амилоидозе
RU2260599C2 (ru) * 1999-03-04 2005-09-20 Прикис Фамэсьютикэлс Инкопэрейтид МОДУЛЯТОР АГРЕГАЦИИ ПЕПТИДА β-АМИЛОИДА ДЛЯ ИНГИБИРОВАНИЯ АГРЕГАЦИИ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА ИЛИ ДЛЯ ЛЕЧЕНИЯ СУБЪЕКТА ОТ НАРУШЕНИЯ, АССОЦИИРОВАННОГО С β -АМИЛОИДОЗОМ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЕТЕКЦИИ В БИОЛОГИЧЕСКОМ ОБРАЗЦЕ ПЕПТИДОВ ПРИРОДНОГО β -АМИЛОИДА
WO2003070760A2 (en) * 2002-02-20 2003-08-28 F. Hoffmann-La Roche Ag Anti-amyloid beta antibodies and their use

Also Published As

Publication number Publication date
RS52004B (sr) 2012-04-30
US9272031B2 (en) 2016-03-01
CN101351476A (zh) 2009-01-21
RU2008128138A (ru) 2010-01-20
PE20100748A1 (es) 2010-11-12
ECSP088524A (es) 2008-07-30
AR057233A1 (es) 2007-11-21
PT1960428E (pt) 2011-10-07
HK1176075A1 (en) 2013-07-19
PL1960428T3 (pl) 2012-02-29
AU2006326301B2 (en) 2011-04-21
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
CN102659943A (zh) 2012-09-12
IL191004A (en) 2013-08-29
EP1960428B1 (en) 2011-07-27
UY30003A1 (es) 2007-08-31
JO2824B1 (en) 2014-09-15
US8906370B2 (en) 2014-12-09
MA30038B1 (fr) 2008-12-01
NZ568241A (en) 2011-08-26
SI1960428T1 (sl) 2011-10-28
KR20080077132A (ko) 2008-08-21
EP2377886A1 (en) 2011-10-19
UA99097C2 (ru) 2012-07-25
BRPI0619605B1 (pt) 2019-08-13
ATE517923T1 (de) 2011-08-15
BRPI0619605B8 (pt) 2021-05-25
DOP2006000278A (es) 2007-07-15
CA2632828C (en) 2012-07-10
TWI382990B (zh) 2013-01-21
NO20082874L (no) 2008-08-28
ZA200805038B (en) 2009-06-24
JP5145241B2 (ja) 2013-02-13
BRPI0619605A2 (pt) 2011-10-11
DK1960428T3 (da) 2011-08-22
KR20120089483A (ko) 2012-08-10
ES2368591T3 (es) 2011-11-18
CY1114783T1 (el) 2016-12-14
HK1130066A1 (en) 2009-12-18
CN102659943B (zh) 2015-07-01
US20090252724A1 (en) 2009-10-08
PE20071002A1 (es) 2007-11-19
NO346105B1 (no) 2022-02-21
MY155286A (en) 2015-09-30
CN101351476B (zh) 2013-04-03
CR10000A (es) 2008-07-29
US20150165022A1 (en) 2015-06-18
WO2007068429A1 (en) 2007-06-21
JP2009520691A (ja) 2009-05-28
TW200736273A (en) 2007-10-01
PE20100684A1 (es) 2010-10-04
KR101401159B1 (ko) 2014-05-29
EP1960428A1 (en) 2008-08-27
AU2006326301A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
RU2438706C2 (ru) Антитела к амилоиду бета 4, имеющие гликозилированную вариабельную область
EP3042917B1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2009520691A5 (https=)
US8623365B2 (en) Aβ binding molecules
US8066999B2 (en) PEGylated Aβ fab
CA2478049A1 (en) Humanized antibodies that recognize beta amyloid peptide
RU2003107564A (ru) Антитела к человеческому il-1бета
AU2018263935A1 (en) Antibodies recognizing tau
JP2003523764A5 (https=)
US10519225B2 (en) Anti-PACAP antibody
WO2012021475A2 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
CA2509068A1 (en) Antibody ("11c7") anti nogo a and its pharmaceutical use
AU2014233615A1 (en) Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof
AU2013231065B2 (en) Pegylated Aß Fab
HK1180703B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof